A deeper understanding of the biology of PSMA in PCa is needed to elucidate pharmacological strategies that can help tackle the heterogeneity in PSMA expression (Figure 7D) and thus enhance the efficacy of PSMA-targeted therapies for advanced PCa. Here, FOLH1 is linked to posterior cortical atrophy.